Supplementary Financial Results Materials for the Interim Accounting Period (April–September) of the Fiscal Year Ending March 2027 (Consolidated IFRS) | ONO PHARMACEUTICAL CO.,LTD. (4528) timely disclosure

Worth reading

43Recurring

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

-246

¥100 million

Wording

Conditional

How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportInterim accounting period for the fiscal year ending March 20275 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥2,325 100 million-9.6%

Results for the three months of the current quarter

Revenue from major products

OPDIVO Intravenous Infusion

April–June¥282 100 million

July–September¥290 100 million

ORENCIA Subcutaneous Injection

April–June¥48 100 million

July–September¥48 100 million

VONJO Tablets

April–June¥32 100 million

July–September¥30 100 million

Parsabiv Injection for Dialysis

April–June¥24 100 million

July–September¥26 100 million

Ongentys Tablets

April–June¥26 100 million

July–September¥26 100 million

Glactiv Tablets

April–June¥31 100 million

July–September¥31 100 million

Braftovi Capsules

April–June¥20 100 million

July–September¥20 100 million

Kyprolis Intravenous Infusion

April–June¥18 100 million

July–September¥17 100 million

QINLOCK

April–June¥117 100 million

July–September¥110 100 million

Lomvimza

April–June¥41 100 million

July–September¥46 100 million

Opdivo (overseas)

April–June¥35 100 million

July–September¥37 100 million

Full-year earnings forecast

Revenue

¥4,550 100 million

Core operating profit

¥1,240 100 million

Core net income attributable to owners of the parent

¥930 100 million

Products and merchandise

¥2,700 100 million

Royalties and other

¥1,850 100 million

Cost of sales

¥840 100 million

R&D Expenses

¥1,430 100 million

Selling, general and administrative expenses (excluding R&D expenses)

¥1,010 100 million

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Interim revenue

Products and merchandise

First half of the fiscal year ending March 2026¥1,750 100 million

Interim period of the fiscal year ending March 2027¥1,361 100 million

Royalties and other

First half of the fiscal year ending March 2026¥822 100 million

Interim period of the fiscal year ending March 2027¥964 100 million

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

R&D expense as a percentage of revenue>30%

New initiatives

Start of an international Phase 3 trial of ONO-4578 in gastric cancer
Start of an international Phase 3 trial of ONO-2808 in multiple system atrophy
Start of a Phase 2 trial of ONO-4915 in Sjögren's disease
Xcopri approved in Japan
Execution of an exclusive licensing agreement with Biohaven for BHV-1300

Number of employees

End-September 20264,207 people

Change during the periodUp 1 from 4,206 as of the end of March 2026

Capital expenditures

¥290 100 million

Contents of this document
Item	Details
Document type	Supplementary materials to the earnings report
Fiscal Period Covered	Interim accounting period for the fiscal year ending March 2027
Net Sales	¥2,325 100 million (YoY -9.6%)
Results for the three months of the current quarter	Revenue Not disclosed / Revenue from major products OPDIVO Intravenous Infusion April–June ¥282 100 million / July–September ¥290 100 million / ORENCIA Subcutaneous Injection April–June ¥48 100 million / July–September ¥48 100 million / VONJO Tablets April–June ¥32 100 million / July–September ¥30 100 million / Parsabiv Injection for Dialysis April–June ¥24 100 million / July–September ¥26 100 million / Ongentys Tablets April–June ¥26 100 million / July–September ¥26 100 million / Glactiv Tablets April–June ¥31 100 million / July–September ¥31 100 million / Braftovi Capsules April–June ¥20 100 million / July–September ¥20 100 million / Kyprolis Intravenous Infusion April–June ¥18 100 million / July–September ¥17 100 million / QINLOCK April–June ¥117 100 million / July–September ¥110 100 million / Lomvimza April–June ¥41 100 million / July–September ¥46 100 million / Opdivo (overseas) April–June ¥35 100 million / July–September ¥37 100 million
Full-year earnings forecast	Revenue ¥4,550 100 million / Core operating profit ¥1,240 100 million / Core net income attributable to owners of the parent ¥930 100 million / Products and merchandise ¥2,700 100 million / Royalties and other ¥1,850 100 million / Cost of sales ¥840 100 million / R&D Expenses ¥1,430 100 million / Selling, general and administrative expenses (excluding R&D expenses) ¥1,010 100 million
Breakdown of Factors Affecting the Change	Interim revenue Products and merchandise First half of the fiscal year ending March 2026 ¥1,750 100 million / Interim period of the fiscal year ending March 2027 ¥1,361 100 million / Royalties and other First half of the fiscal year ending March 2026 ¥822 100 million / Interim period of the fiscal year ending March 2027 ¥964 100 million
Number of employees	End-September 2026 4,207 people / Change during the period Up 1 from 4,206 as of the end of March 2026
Assumptions Underlying the Business Outlook	R&D expense as a percentage of revenue >30%
Capital expenditures	¥290 100 million
New initiatives	Start of an international Phase 3 trial of ONO-4578 in gastric cancer, Start of an international Phase 3 trial of ONO-2808 in multiple system atrophy, Start of a Phase 2 trial of ONO-4915 in Sjögren's disease, Xcopri approved in Japan, Execution of an exclusive licensing agreement with Biohaven for BHV-1300

Items this document does not state (21)

Operating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesProgress against full-year forecastSelf-assessment against the planSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

During the interim period, revenue from products and merchandise decreased from ¥175.0 billion in the same period of the previous year to ¥136.1 billion, while royalties and other revenue increased from ¥82.2 billion to ¥96.4 billion. For its full-year forecast, the company cited lower product and merchandise revenue and co-promotion expenses following the end of the co-promotion agreement for Forxiga tablets, higher royalty income and continued research and development investment.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.